GlassScriptPhysician profile
Aditya Kadiyala
NPI 1811131774
$2,847.53
in general payments reported to CMS, 2019-2025
21 companies · $757 in 2025
The $757 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $411 · 2021: $219 · 2022: $387 · 2023: $484 · 2024: $589 · 2025: $757.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,665 · Education: $166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,665.06 |
| Education | $165.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $375.80 | 2019-2025 | Farxiga, Lokelma |
| Ardelyx, INC. | $325.04 | 2024-2025 | Ibsrela, Xphozah 30 Mg |
| Vifor Pharma, INC. | $251.70 | 2019-2025 | Veltassa |
| Akebia Therapeutics INC | $249.87 | 2019-2025 | Auryxia, Vafseo |
| Bayer Healthcare Pharmaceuticals INC. | $237.81 | 2021-2024 | |
| Opko Pharmaceuticals, LLC | $233.43 | 2019-2025 | Rayaldee |
| Travere Therapeutics, INC. | $155.85 | 2023-2025 | Filspari |
| Calliditas Therapeutics US INC. | $141.20 | 2022-2025 | Tarpeyo |
| Novo Nordisk INC | $139.18 | 2024-2025 | Ozempic, Rybelsus |
| Fresenius USA Marketing, INC. | $130.71 | 2019-2024 | Velphoro |
| Otsuka America Pharmaceutical, INC. | $120.05 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $93.65 | 2025 | |
| Baxter Healthcare | $66.28 | 2019 | |
| Lilly USA, LLC | $61.59 | 2024 | Jardiance |
| Amgen INC. | $60.28 | 2021-2025 | Krystexxa |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $47.11 | 2019-2025 | Ultomiris |
| Aurinia Pharma U.S., INC. | $46.27 | 2023 | Lupkynis |
| Glaxosmithkline, LLC. | $34.09 | 2022-2023 | Benlysta |
| Mallinckrodt Enterprises LLC | $29.44 | 2019 | |
| Qiagen, LLC | $29.22 | 2025 | |
| Scpharmaceuticals INC. | $18.96 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aditya Kadiyala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.